Large-vessel giant cell arteritis: A cohort study

Rheumatology (United Kingdom)

Volumn 54, Issue 3, 2015, Pages 463-470

  Muratore, Francesco ^a   Kermani, Tanaz A ^b   Crowson, Cynthia S ^c   Green, Abigail B ^c   Salvarani, Carlo ^a   Matteson, Eric L ^c   Warrington, Kenneth J ^c  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Giant cell arteritis; Imaging; Large vessel vasculitis; Prognosis; Treatment

Indexed keywords

PREDNISONE; CORTICOSTEROID;

ADULT; AGED; ARM; ARTICLE; BIOPSY; COHORT ANALYSIS; CORTICOSTEROID THERAPY; FEMALE; GIANT CELL ARTERITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE VESSEL GIANT CELL ARTERITIS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOGRAPHY; RELAPSE; RETROSPECTIVE STUDY; VISUAL IMPAIRMENT; CLASSIFICATION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; PATHOLOGY; PREVALENCE; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY; VISION DISORDERS;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GIANT CELL ARTERITIS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISION DISORDERS;

EID: 84941619691     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu329     Document Type: Article

References (28)

1. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347:261-71.
2. NuenninghoffDM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003;48:3522-31.
3. Bongartz T, Matteson EL. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 2006;18:10-7.
4. Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975;83:806-12.
5. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999;42:311-7.
6. Kermani TA, Matteson EL, Hunder GG, Warrington KJ. Symptomatic lower extremity vasculitis in giant cell arteritis: a case series. J Rheumatol 2009;36:2277-83.
7. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-45.
8. Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 1995;24:422-31.
9. Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology 2008;47:96-101.
10. Ghinoi A, Pipitone N, Nicolini A et al. Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology 2012;51:730-4.
11. Aschwanden M, Kesten F, Stern M et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions. Ann Rheum Dis 2010;69:1356-9.
12. Prieto-González S, Arguis P, García-Martínez A et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis 2012;71:1170-6.
13. Blockmans D, de Ceuninck L, Vanderschueren S et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006;55:131-7.
14. Schmidt WA, Moll A, Seifert A et al. Prognosis of largevessel giant cell arteritis. Rheumatology 2008;47:1406-8.
15. NuenninghoffDM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003;48:3532-7.
16. Kermani TA, Warrington KJ, Crowson CS et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 2013;72:1989-94.
17. Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
18. Stanson AW. Imaging findings in extracranial (giant cell) temporal arteritis. Clin Exp Rheumatol 2000;18(Suppl 20): S43-8.
19. Assie C, Janvresse A, Plissonnier D, Levesque H, Marie I. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients. Medicine 2011;90:40-51.
20. Both M, Schulte K, Moosig F et al. High white blood cell count in patients with giant cell arteritis predicts an increased risk of stenosis in upper extremity arteries. Ann Rheum Dis 2011;70:1879-80.
21. Brodmann M, Lipp RW, Passath A et al. The role of 2-18Ffluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries. Rheumatology 2004;43:241-2.
22. Yun M, Yeh D, Araujo LI et al. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med 2001;26:314-9.
23. Cantini F, Niccoli L, Storri L et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum 2004;33:294-301.
24. González-Gay MA, Garcia-Porrua C, Rivas MJ, Rodriguez-Ledo P, Llorca J. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis 2001;60:367-71.
25. Moosig F, Czech N, Mehl C et al. Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann Rheum Dis 2004;63: 870-3.
26. Blockmans D, De Ceuninck L, Vanderschueren S et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology 2007;46:672-7.
27. Cimmino MA, Zampogna G, Parodi M. Is FDG-PET useful in the evaluation of steroid-resistant PMR patients? Rheumatology 2008;47:926-7.
28. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-8.